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ABSTRACT
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of
morbidity and mortality with younger women being disproportionately affected by traditional
risk factors including dyslipidemia. Despite recommendations for lipid screening in early
adulthood, many younger women currently do not undergo screening. Prenatal and early
pregnancy care represent underutilized opportunities for lipid screening and ASCVD risk
assessment. We aimed to assess the prevalence and variations in pregnant women reporting a
prior lipid screening and an awareness of high cholesterol as a risk factor for ASCVD.

METHODS: We administered a survey to 234 pregnant women receiving prenatal care at one of
the three clinics affiliated with the University of Pennsylvania Health System to assess selfreported demographic and clinical variables, prior lipid screening characteristics, and risk factor
awareness. Participants’ responses were augmented by screening data and previous lipid profile
results from their electronic medical records (EMR).

RESULTS: A total of 200 pregnant women (86% response rate) completed the survey. Overall,
59% of pregnant women self-reported a previous lipid screening and 79% of women were aware
of high cholesterol as an ASCVD risk factor. Stratified by racial/ethnic subgroups non-Hispanic
(NH) Black women were less likely to report a prior screening (43% vs. 67%, p=0.022) and had
lower levels of risk factor awareness (66% vs. 92%, p<0.001) compared with NH white women.
While NH Black women were more likely to see an obstetrician/gynecologist (OB/GYN) for
their usual source of non-pregnancy care compared with NH white women (18% vs. 5%,
p=0.043), those seeking an OB/GYN were significantly less likely to receive a prior lipid
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screening compared to those seeing a primary care physician (29% vs. 63%, p=0.007). Stepwise
associations were observed between the presence of both a prior lipid screening and risk factor
awareness with education and annual household income. After adjusting for covariates, NH
Black women were more likely to lack prior screening (OR, 3.35; 95% CI, 1.29 – 8.67, p=0.013).

CONCLUSIONS: Significant racial/ethnic and sociodemographic disparities persist in both the
presence of a prior lipid screening and awareness of high cholesterol as an ASCVD risk factor.
Prenatal and early pregnancy care are underutilized opportunities to enhance lipid screening
among younger women and reduce variations in access to preventive care.
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INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and
mortality among women in the United States.1 Though recent data show an overall decline in
ASCVD incidence and mortality, a stagnation in population-level improvements has been
observed among younger women (<55 years).2-4 The increased prevalence of traditional ASCVD
risk factors such as diabetes, obesity and overweight, hypertension, and dyslipidemia may
contribute to the current trends.3 Compared with all other known ASCVD risk factors,
dyslipidemia represents a leading population-adjusted risk among women.5 Moreover, younger
women with undiagnosed and undertreated lipid disorders, including familial
hypercholesterolemia (FH), are known to be at greater risk for developing early ASCVD.6
Despite recommendations for screening for lipid disorders in early adulthood, less than half of
women have had a prior lipid screening, with considerable disparities existing for racial/ethnic
minority and sociodemographic disadvantaged populations.1,7-13 Therefore, novel strategies are
needed to increase access to and utilization of lipid screening for young women to prevent early
ASCVD and identify potential lipid disorders.
Considering that approximately 86% of women will have experienced at least 1
pregnancy by age 45 years,14 prenatal and early pregnancy care represent a unique period during
which a large proportion of women receive preventive care, though lipid screening has not
routinely been performed during this period.14,15 Marked changes in lipid levels – particularly in
total cholesterol and triglycerides – occur by the second and third trimesters, however, the
majority of women receive prenatal care beginning in the first trimester of pregnancy, prior to
significant changes in lipid metabolism.14,16-22 Pregnancy, often referred to as a cardiometabolic
“stress test,” along with the pre-pregnancy period represent a unique and currently underutilized
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opportunity to not only screen for potential lipid disorders among younger women, but also to
utilize OB/GYN history to inform ASCVD risk reduction strategies and/or referral patterns to a
primary care physician or cardiovascular specialist during the postpartum period.2,23
Accordingly, the objective of this cross-sectional survey study was to assess the
prevalence of prior lipid screening and awareness of high cholesterol as an ASCVD risk factor
among pregnant women. Additionally, we aimed to better characterize differences in screening
and awareness based on race/ethnicity and sociodemographic characteristics in our urban
population of women receiving prenatal care.

METHODS
Study Design and Participants
This cross-sectional survey study sought to assess the prevalence and variations in lipid
screening and risk factor awareness among pregnant women receiving prenatal care from one of
three clinics affiliated with the University of Pennsylvania Health System (UPHS) between May
– August 2019. Surveys were administered in-person to pregnant, English-speaking women 18
years of age or older prior to their prenatal care visit. After obtaining informed consent forms
and completed surveys, clinical variables and lipid screening characteristics were abstracted from
participants’ electronic medical records (EMR). Racial/ethnic differences were assessed upon
stratifying participants based on race (white, Black, Asian, or multiracial) and ethnicity
(Hispanic or non-Hispanic). Due to limited sample size for Hispanic, Asian, and multiracial
subgroups, analyses were conducted among non-Hispanic (NH) white and NH Black women.
Pregnant women were excluded if they were younger than 18 years of age or if they were not
proficient in English.
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Survey Development and Administration
We developed a survey that assessed pregnant women’s demographic and clinical
characteristics including race/ethnicity, highest level of completed education, annual household
income, family history of high cholesterol and ASCVD, and current and/or former health
conditions during pregnancy such as gestational diabetes, gestational hypertension, and
preeclampsia. The presence of a previous premature birth was defined as delivery <37 weeks’
gestation. Participants’ gestational age was categorized by trimester at the time of survey
completion. We also assessed whether women had a usual source of non-pregnancy care and if
so, with what type of healthcare provider (survey questions in supplemental materials).
Our main outcomes included a self-reported presence of prior lipid screening and an
awareness of high cholesterol as an ASCVD risk factor. Among women reporting prior
screening, we assessed the timing of screening (within past year, 2 years, or 5 years or longer)
and the type of provider who ordered the screening test (primary care physician, OB/GYN, or
other). Finally, we assessed participants’ acceptability of lipid screening during early pregnancy
on a 5-point Likert scale (strongly disagree to strongly agree) after providing a brief passage
regarding the potential risk and benefits.

Electronic Medical Record (EMR) Data Collection
Upon survey completion, we reviewed each respondent’s medical records to assess
additional clinical characteristics and documentation of prior lipid screening results. Specifically,
we abstracted prior levels of low-density lipoprotein-cholesterol (LDL-C), high-density
lipoprotein-cholesterol (HDL-C), total cholesterol, and triglycerides (in mg/dL). The timing of
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prior EMR-documented screening was determined by the elapsed time between test date and
survey completion. Six participants had missing EMR data and were excluded from EMR
aspects of subsequent statistical analyses yielding an overall sample of 194 women with
complete data. Analyses based on racial/ethnic differences in EMR-documented lipid levels were
conducted to include all documented lipid profile results as well as a subsequent sensitivity
analysis excluding results from one woman with suspected undiagnosed FH, based on Dutch
Lipid Clinic Network diagnostic criteria.24-26

Statistical Analyses
We analyzed continuous and categorical descriptive data using two-tailed t test and chisquare analysis or Fisher’s exact test, respectively. We conducted logistic regression analysis to
ascertain the association between participants’ characteristics and absence of prior lipid
screening and lack of awareness of high cholesterol as an ASCVD risk factor. Self-reported
screening and risk factor awareness were dichotomized into “yes” and “no/unsure” due to the
relatively small sample size. Odds ratios (OR) and 95% confidence intervals (CI) were produced
for unadjusted and adjusted associations. Our final model for logistic regression analyses
adjusting for age, race/ethnicity, education level, and usual source of care was developed based
on a backward elimination strategy, in which variables were removed individually from an
originally full model to produce the most parsimonious final model.27 A p-value < 0.05 was
considered statistically significant. Analyses were conducted with SAS, version 9.4 (SAS Inc.,
Cary, North Carolina). The protocol was approved by the Institutional Review Board at the
University of Pennsylvania.
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RESULTS
We approached 234 pregnant women receiving prenatal care at UPHS and 200 women
completed the surveys (85.5% response rate). Overall, 68% of participants were < 35 years of
age (mean [±SD] age, 32.2 [±5.7] years) and approximately half (51%) were more than 28
weeks’ gestation at the time of survey completion (Table 1). We observed the following
racial/ethnic distribution in our sample: 46% NH white, 34% NH Black, 9% Asian, 6% Hispanic,
and 5% multiracial women. In our sample population, 59% of women had completed college or
higher and 47% of participants indicated an annual household income of more than $100,000.
We found that 88% of women had a usual source of non-pregnancy care, with 90% reporting
receiving care from a primary care physician or family medicine practitioner and only 10% from
an OB/GYN. Additionally, 35% and 16% of women reported having a family history of high
cholesterol and ASCVD, respectively.
We found significant differences in demographic and clinical characteristics between NH
Black women and NH white women (Table 1). Notably, a greater proportion of NH white
women were ³ 35 years of age compared with NH Black women (41% vs. 18%, p=0.004).
Additionally, NH white women were more likely to have completed college or higher compared
with NH Black women (82% vs. 27%, p<0.001) and more likely to report an annual household
income more than $100,000 compared with NH Black women (74% vs. 10%, p<0.001). Our
results also showed that NH white women were less likely to indicate that an OB/GYN was their
usual source of non-pregnancy care compared with NH Black women (5% vs. 18%, p=0.043).
Overall, 118 (59%) pregnant women reported a previous lipid screening, with the
majority of participants (57%) indicating that they received this screening within the past year
(Table 2). Among women with prior screening, 63% and 19% of women received screening from
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a primary care physician and OB/GYN, respectively. We found that 79% of participants were
aware of high cholesterol as a risk factor for ASCVD and 71% found lipid screening during early
pregnancy acceptable. When stratified by race, we observed that NH white women were more
likely to self-report a prior lipid screening (67% vs. 43%, p=0.022) and more likely to be aware
of high cholesterol as an ASCVD risk factor (92% vs. 66%, p<0.001) compared with NH Black
women. Acceptability of lipid screening during pregnancy was similar between NH white and
NH Black women.
Figure 1 shows baseline characteristics associated with self-reported history of lipid
screening, including age ³ 35 compared to < 35 years (53% vs. 72%, p=0.011) and NH white
race compared to NH Black race (67% vs. 43%, p=0.007). Highest completed level of education
was associated with a stepwise increase in screening rates. Baseline characteristics associated
with awareness of high cholesterol as an ASCVD risk factor included age ³ 35 compared to < 35
years (88% vs. 75%, p=0.041), NH white compared to NH Black race (92% vs. 66%, p<0.001)
and having a usual source of non-pregnancy care compared to not having usual care (82% vs
63%, p=0.003). Both highest completed level of education (p=0.006) and household income
(p=0.003) were associated with a stepwise increase in screening rates. Family history of high
cholesterol or cardiovascular disease were not associated with prior screening or awareness of
high cholesterol as an ASCVD risk factor.
The results of the unadjusted and adjusted analyses are presented in Table 3. Based on
our unadjusted analysis of factors associated with greater odds of lacking prior lipid screening,
we found significant associations based on younger age (OR, 2.28; 95% CI, 1.20 – 4.33), NH
Black race/ethnicity (OR, 2.73; 95% CI, 1.43 – 5.24), lower education level (OR, 3.76; 95% CI,
1.77 – 8.00), and lower household income (OR, 2.23; 95% CI, 1.16 – 4.30). After adjusting for
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age, race/ethnicity, education, and usual source of non-pregnancy care, we found that NH Black
race/ethnicity remained statistically significant (OR, 3.35; 1.29 – 8.67). Similarly, we found
significant unadjusted associations between lack of risk factor awareness and younger age (OR,
2.35; 95% CI, 1.02 – 5.44), NH Black race/ethnicity (OR, 6.13; 95% CI, 2.44 – 15.39), lower
education level (OR, 3.43; 95% CI, 1.49 – 7.92), lower household income (OR, 4.19; 95% CI,
1.61 – 10.95), and no usual source of care (OR, 2.66; 95% CI, 1.07 – 6.62). After adjusting for
these covariates, NH Black race/ethnicity (OR, 8.92; 95% CI, 2.07 – 38.42) and no usual source
of care (OR, 8.60; 95% CI, 1.73 – 42.69) remained statistically significant.
Upon our abstraction of EMR data, only 62 (32%) women had evidence of prior lipid
screening (Table 4). NH white women had higher rates of lipid screening compared with NH
Black women (39% vs. 19%, p=0.016). We identified one NH Black participant with suspected
FH who had not yet been formally diagnosed. Excluding this participant, the mean (SD) values
were: total cholesterol of 174.4 (28.5) mg/dL, LDL-C of 96.7 (25.8) mg/dL, HDL-C of 60.9
(13.4) mg/dL, and triglycerides of 84.2 (40.8) mg/dL. NH white women had significantly higher
HDL-C levels compared with NH Black women (63 vs. 52 mg/dL, p=0.048).

DISCUSSION
In a population of pregnant women receiving prenatal care in a large, racially diverse
urban area, we found that 59% of participants reported a prior lipid screening. Our findings
demonstrated significant disparities in lipid screening by age, race/ethnicity, and education along
with differences in risk factor awareness by these characteristics along with household income
and usual source of care status. Notably, we found that NH Black women were less likely to
report prior screening (43% vs. 67%, p=0.022) and had lower rates of risk factor awareness (66%
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vs. 92%, p<0.001) compared with NH white women. After adjusting for covariates, NH Black
women were significantly more likely to lack a prior lipid screening. NH Black women and those
without a usual source of care also had greater odds of being unaware of high cholesterol as a
cardiovascular risk factor upon adjusting for covariates.
Though prior studies have provided evidence for racial/ethnic and sociodemographic
differences in lipid screening practices,9,11,12,28-30 our cross-sectional survey represents one of the
first studies demonstrating disparities in lipid screening and risk factor awareness among
pregnant women receiving prenatal care. Our overall lipid screening prevalence of 59%
corresponded to those previously observed. For instance, one study conducted by Kuklina and
colleagues reported a lipid screening rate of approximately 50%, with minimal variations
depending on the number of relative ASCVD risk factors present.8 Lower socioeconomic status,
lack of healthcare access, immigration status, and language barriers have also been shown to be
significant predictors of racial and ethnic disparities in lipid screening.9,11 Notably, our results
align with population-level data from the National Health and Nutrition Examination Surveys
(NHANES) that found that NH white individuals were more likely to be screened for high blood
cholesterol levels compared with NH Black individuals (65% vs. 58%).31
In addition to observing differences in lipid screening rates by self-report and through
assessment of participants’ medical records, significant racial/ethnic differences were identified
in awareness of high cholesterol as a risk factor for ASCVD. Our work can be interpreted
alongside other studies that have assessed awareness of high cholesterol as a key modifiable risk
factor. In a nationally representative sample of more than one thousand women, Mosca et al.
found that an awareness of increased ASCVD burden over time was higher in white women than
Black women (62% vs. 38%) and was independently correlated with increased physical activity
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and weight loss.32 The authors found that only 46% of women could recall their lipid levels and
that white women were significantly more knowledgeable of healthy lipid levels than either
Black or Hispanic women (p<0.05).32 Lastly, Huang and colleagues found that, among nearly
40,000 women without ASCVD in the Women’s Health Study, women who were aware of their
lipid levels had higher incomes and were more educated when compared to those who were
unaware,33 findings similar to the stepwise associations currently presented.
For inherited conditions of lipid metabolism such as FH, novel approaches are urgently
needed for identifying proband patients and initiating cascade screening in family members when
applicable. With approximately 90% of those with FH remaining undiagnosed and significant
racial/ethnic disparities observed based on LDL-C achievement among those with FH,24,25,34
interdisciplinary strategies for integrating screening and cardiovascular risk assessment during a
period of greater healthcare utilization may translate into a higher yield of case identification and
subsequent cascade screening.35 Since preventive health visits to an OB/GYN provider are often
focused on reproductive health-related services, women of reproductive age who utilize
OB/GYN services primarily for preventive care may not be receiving a comprehensive spectrum
of preventive screenings, counseling, and follow-up care.15 Our results show that women who
identify their OB/GYN as their primary care provider were less likely to undergo lipid screening
compared to those seeing an internal medicine or family medicine practitioner (63% vs. 29%,
p=0.007). Leveraging the perinatal period is currently an underutilized opportunity to screen for
potential lipid disorders, promote primary prevention of ASCVD, and inform necessary followup care and counseling if needed.36-38
Engaging OB/GYN practitioners has been identified as a potential strategy for enhancing
ASCVD prevention considering the high-frequency in which women receive healthcare services
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from OB/GYNs during reproductive years, though barriers to effective screening, management,
and referrals have been reported.39-41 One national survey of OB/GYNs found that, while 61% of
practitioners provided more than reproductive care when providing well-woman care, they were
unlikely to manage elevated lipid levels.42 Moreover, in a focus group of OB/GYNs, knowledge
gaps and skills deficits along with liability concerns and barriers to prevention were identified as
practice barriers.40 Increased awareness initiatives, educational interventions, and
multidisciplinary partnerships are needed to effectively communicate the reliability of lipid
screening tests during early pregnancy, particularly during the first trimester before significant
changes in lipid metabolism occur.
Racial differences in prior lipid screening were also observed upon review of
participants’ EMR data. Overall, fewer patients had EMR-documented lipid screening compared
to self-report. This may be a result of patients undergoing lipid screening at other testing sites or
through workplace wellness programs as well as being attributable to participant recall bias.
Among the 194 women without missing EMR data, we identified at least one probable FH case
that had not been previously evaluated by a lipid or cardiovascular specialist. While plasma
cholesterol and triglyceride levels have been shown to increase by 25% to 50% and 150% to
300%, respectively, during pregnancy, women with FH experience a higher absolute increase in
lipid levels, thus potentially putting them at greater risk for accelerated atherosclerosis.43,44
Though statins and other lipid-lowering medications such as ezetimibe and monoclonal
antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are
contraindicated and therefore not recommended during pregnancy and lactation, identifying FH
earlier in life is critical for initiating appropriate postpartum follow-up care including lipidlowering agents.36 Engaging OB/GYNs as a key partner in ASCVD prevention, management,
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and counseling represents a unique opportunity to screen for potential lipid disorders, assess
future cardiovascular risk, and leverage specialists for postpartum follow-up care.2,38-40

Limitations
Our findings should be interpreted considering several limitations. First, responses to our
survey may have been subject to response and/or recall bias. Despite aiming to survey all eligible
women present in the waiting room during survey administration visits and an overall high
response and completion rate, the risk residual confounding cannot be discounted. Second, the
retrospective review of the EMR did not capture all relevant clinical characteristics and was
subject to missing data. Third, our sample size limited our ability to further evaluate associations
between lipid screening and risk factor awareness with sociodemographic characteristics in other
subgroups. Fourth, the presence of confounding after adjustment may have contributed to the
larger effect estimates than those observed in unadjusted associations and the relatively small
sample size may have contributed to the presence of several wider confidence intervals. Fifth,
our study utilized an investigator-developed survey instrument, thereby strengthening the case
for implementing future validation studies in larger, nationally representative cohorts. Lastly, the
external validity of our findings was limited to English-speaking, pregnant women receiving
prenatal care in an urban setting and may not be generalizable to other populations.

CONCLUSION
Despite current guidelines recommending focused screening for lipid disorders in
childhood, adolescence, and early adulthood, we found that 2 in 5 pregnant women did not report
a prior lipid screening and 1 in 3 were unaware of high cholesterol as an ASCVD risk factor.
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Significant racial/ethnic and sociodemographic disparities were associated with both a prior
screening as well as risk factor awareness. Leveraging prenatal and early pregnancy care is
currently an underutilized opportunity to enhance lipid screening among younger women,
identify potential lipid disorders, and reduce current variations in access to preventive
cardiovascular care.
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FIGURES
Figure 1. Self-reported lipid screening and risk factor awareness stratified by sociodemographic
characteristics including age, race/ethnicity, highest level of completed education, household
income, and usual source of care status
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* P < 0.10, ** P < 0.05, *** P < 0.01
Abbreviations: GED, general education diploma

26

TABLES
Table 1. Overall demographic and clinical characteristics among pregnant women and
differences stratified by all racial/ethnic subgroups
Study Variables

Overall Population
(N=200)*
32.2 (5.7)

NH White
(N=91)
34.1 (5.0)

NH Black
(N=68)
29.6 (5.8)

Age, mean (SD)
Age Categories, years
18 – 34
133 (67.9)
53 (58.9)
56 (82.4)
35+
63 (32.1)
37 (41.1)
12 (17.7)
Race/Ethnicity
NH White
91 (45.5)
91 (100.0)
0 (0.0)
NH Black
68 (34.0)
0 (0.0)
68 (100.0)
Asian
18 (9.0)
0 (0.0)
0 (0.0)
Hispanic
12 (6.0)
0 (0.0)
0 (0.0)
Multiracial
9 (4.5)
0 (0.0)
0 (0.0)
Missing
2 (1.0)
0 (0.0)
0 (0.0)
Gestational age (weeks) at time of survey
1 – 13
18 (9.3)
10 (11.2)
6 (9.0)
14 – 27
78 (40.2)
42 (47.2)
22 (32.8)
28+
98 (50.5)
37 (41.6)
39 (58.2)
Education
High school / GED or lower
40 (20.2)
6 (6.6)
28 (41.2)
Some college or associate degree
42 (21.2)
10 (11.0)
22 (32.4)
College graduate or above
116 (58.6)
75 (82.4)
18 (26.5)
Annual Household Income
Less than $20,000
19 (11.7)
3 (3.7)
11 (21.6)
$20,000 – $49,999
32 (19.8)
3 (3.7)
23 (45.1)
$50,000 – $99,999
35 (21.6)
15 (18.5)
12 (23.5)
More than $100,000
76 (46.9)
60 (74.1)
5 (9.8)
Usual Source of Non-Pregnancy Care
Yes
172 (87.8)
77 (85.6)
63 (92.7)
No
24 (12.2)
13 (14.4)
5 (7.4)
Non-Pregnancy Care Provider Type
Primary care, family medicine
153 (90.0)
71 (94.7)
52 (82.5)
OB/GYN
17 (10.0)
4 (5.3)
11 (17.5)
Family History of High Cholesterol
Yes
67 (34.5)
43 (47.8)
11 (16.4)
No
95 (49.0)
36 (40.0)
40 (59.7)
Unsure
32 (16.5)
11 (12.2)
16 (23.9)
Family History of Cardiovascular Disease
Yes
32 (16.2)
13 (14.3)
11 (16.4)
No
156 (83.8)
78 (85.7)
56 (83.6)
Past OB History
Gestational diabetes
17 (8.6)
6 (6.6)
6 (8.8)
Gestational hypertension
13 (6.6)
7 (7.7)
6 (8.8)
Preeclampsia
18 (9.1)
6 (6.6)
10 (14.7)
Premature birth (<37 weeks’ gestation)
17 (8.6)
5 (5.5)
10 (14.7)
* P-value represents statistical comparison between NH White and NH Black subgroups
Abbreviations: GED, general education diploma; NH, non-Hispanic; OB/GYN, obstetrician/gynecologist

P-Value
<0.001
0.004
---

0.214

<0.001

<0.001

0.330
0.043
0.002

0.548

0.562
0.160
0.123
0.078

27

Table 2. Self-reported lipid screening characteristics and risk factor awareness stratified by nonHispanic white and non-Hispanic Black racial/ethnic subgroups
Screening Characteristics

Overall
(N=200)

NH White
(N=91)

Prior Lipid Screening
Yes
118 (59.0)
61 (67.0)
No
30 (15.0)
11 (12.1)
Unsure
52 (26.0)
19 (20.9)
Timing of Prior Lipid Screening
Within past year
68 (57.1)
29 (48.3)
Within past 2 years
23 (19.3)
11 (18.3)
Within past 5 years or longer
28 (23.5)
20 (33.3)
Type of Provider Ordering Screening
Primary care or family medicine
79 (63.2)
38 (61.3)
OB/GYN
24 (19.2)
11 (17.7)
Other
22 (17.6)
13 (21.0)
Awareness of High Cholesterol as Risk Factor
Yes
158 (79.0)
84 (92.3)
No
35 (17.5)
7 (7.7)
Unsure
7 (3.5)
0 (0.0)
Acceptability of Screening During Pregnancy
Agree
141 (71.2)
63 (69.2)
Neutral
44 (22.2)
22 (24.2)
Disagree
13 (6.6)
6 (6.6)
* P-value represents statistical comparison between NH white and NH Black subgroups
Abbreviations: OB/GYN, obstetrician/gynecologist

NH Black
(N=68)

P-Value*
0.022

29 (42.7)
14 (20.6)
25 (36.8)
0.077
22 (73.3)
6 (20.0)
2 (6.7)
0.355
25 (75.8)
5 (15.2)
3 (9.1)
<0.001
45 (66.2)
16 (23.5)
7 (10.3)
0.610
46 (68.7)
15 (22.4)
6 (9.0)
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Table 3. Unadjusted and adjusted associations between sociodemographic characteristics and
lack of prior cholesterol screening and a lack of awareness of high cholesterol as a
cardiovascular risk factor
Study Variables

Lack of Prior Lipid Screening
Unadjusted

Age, y
18 – 34
³ 35
Race/Ethnicity
NH Black
NH white
Education
£ Some college
³ College graduate
Household Income
< $100,000 / y
³ $100,000 / y
Usual Source of Care
No
Yes

P
Value
0.012

2.28 (1.20 – 4.33)
reference

Adjusted*

P
Value
0.407

1.44 (0.61 – 3.42)
reference
0.002

2.73 (1.43 – 5.24)
reference

0.013

0.001

0.310

0.406
1.66 (0.50 – 5.50)
reference

0.003
4.19 (1.61 – 10.95)
reference

0.100
2.78 (0.82 – 9.37)
reference

0.003
8.92 (2.07 – 38.42)
reference

0.004

---

----reference

0.035
2.66 (1.07 – 6.62)
reference

P
Value
0.517

1.56 (0.41 – 6.00)
reference

3.43 (1.49 – 7.92)
reference

--reference

Adjusted*

< 0.001

0.196

0.017

P
Value
0.046

6.13 (2.44 – 15.39)
reference

1.96 (0.71 – 5.43)
reference

2.23 (1.16 – 4.30)
reference

Unadjusted
2.35 (1.02 – 5.44)
reference

3.35 (1.29 – 8.67)
reference

3.76 (1.77 – 8.00)
reference

1.56 (0.66 – 3.67)
reference

Lack of Risk Factor Awareness

0.009
8.60 (1.73 – 42.69)
reference

Values are presented as odds ratios (OR) and 95% confidence intervals (CI)
* Adjusted for age, race/ethnicity, education, and usual source of non-pregnancy care
Abbreviations: GED, general education diploma; NH, non-Hispanic
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Table 4. Lipid screening characteristics among pregnant women from data abstraction of
electronic medical records stratified by non-Hispanic white and non-Hispanic Black racial/ethnic
subgroups
EMR Screening Characteristics

Overall
(N=194)*

NH White
(N=89)

NH Black
(N=65)

P-Value†

Prior Lipid Screening
0.016
Yes
62 (32.0)
35 (39.3)
12 (18.5)
No
132 (68.0)
54 (60.7)
53 (81.5)
Timing of Prior Lipid Screening (n=62)
0.927
Within past year
16 (25.8)
10 (28.6)
3 (25.0)
Within past 2 years
8 (12.9)
5 (14.3)
2 (16.7)
Within past 5 years
25 (40.3)
13 (37.1)
4 (33.3)
Longer than past 5 years
13 (21.0)
7 (20.0)
3 (25.0)
* Six participants with absence of electronic medical records
† P-value represents statistical comparison between NH White and NH Black subgroups
Abbreviations: EMR, electronic medical records; SD, standard deviation; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol
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SUPPLEMENTAL TABLES
Supplemental Table 1. Overall demographic and clinical characteristics among pregnant
women and differences stratified by all racial/ethnic subgroups
Study Variables
Sample, n (%)
Age, mean (SD)
Age Categories, y
18 – 34
35+
Gestational age (weeks) at time of survey
1 – 13
14 – 27
28+
Education
High school / GED or lower
Some college or associate degree
College graduate or above
Annual Household Income
Less than $20,000
$20,000 – $49,999
$50,000 – $99,999
More than $100,000
Usual Source of Non-Pregnancy Care
Yes
No
Non-Pregnancy Usual Care Provider Type
Primary care, family medicine
OB/GYN
Family History of High Cholesterol
Yes
No
Unsure
Family History of Cardiovascular Disease
Yes
No
Past OB History
Gestational diabetes
Gestational hypertension
Preeclampsia
Premature birth (<37 weeks’ gestation)

Overall
Population
(N=200)*
--32.2 (5.7)

NH White

NH Black

Asian

Hispanic

Multiracial

91 (45.5)
34.1 (5.0)

68 (34.0)
29.6 (5.8)

18 (9.0)
33.6 (4.5)

12 (6.0)
30.3 (6.0)

8 (4.5)
31.3 (6.5)

133 (67.9)
63 (32.1)

53 (58.9)
37 (41.1)

56 (82.4)
12 (17.7)

9 (50.0)
9 (50.0)

10 (83.3)
2 (16.7)

5 (62.5)
3 (37.5)

18 (9.3)
78 (40.2)
98 (50.5)

10 (11.2)
42 (47.2)
37 (41.6)

6 (9.0)
22 (32.8)
39 (58.2)

1 (5.9)
6 (35.3)
10 (58.8)

1 (8.3)
5 (41.7)
6 (50.0)

0 (0.0)
3 (33.3)
6 (66.7)

40 (20.2)
42 (21.2)
116 (58.6)

6 (6.6)
10 (11.0)
75 (82.4)

28 (41.2)
22 (32.4)
18 (26.5)

1 (5.6)
3 (16.7)
14 (77.8)

3 (25.0)
5 (41.7)
4 (33.3)

2 (22.2)
2 (22.2)
5 (55.6)

19 (11.7)
32 (19.8)
35 (21.6)
76 (46.9)

3 (3.7)
3 (3.7)
15 (18.5)
60 (74.1)

11 (21.6)
23 (45.1)
12 (23.5)
5 (9.8)

1 (6.7)
3 (20.0)
4 (26.7)
7 (46.7)

3 (30.0)
2 (20.0)
2 (20.0)
3 (30.0)

1 (20.0)
1 (20.0)
2 (40.0)
1 (20.0)

172 (87.8)
24 (12.2)

77 (85.6)
13 (14.4)

63 (92.7)
5 (7.4)

12 (66.7)
6 (33.3)

11 (100.0)
0 (0.0)

9 (100.0)
0 (0.0)

153 (90.0)
17 (10.0)

71 (94.7)
4 (5.3)

52 (82.5)
11 (17.5)

10 (83.3)
2 (16.7)

11 (100.0)
0 (0.0)

9 (100.0)
0 (0.0)

67 (34.5)
95 (49.0)
32 (16.5)

43 (47.8)
36 (40.0)
11 (12.2)

11 (16.4)
40 (59.7)
16 (23.9)

9 (52.9)
6 (35.3)
2 (11.8)

2 (18.2)
8 (72.7)
1 (9.1)

2 (22.2)
5 (55.6)
2 (22.2)

32 (16.2)
156 (83.8)

13 (14.3)
78 (85.7)

11 (16.4)
56 (83.6)

3 (16.7)
15 (83.3)

2 (16.7)
10 (83.3)

3 (33.3)
6 (66.7)

17 (8.6)
13 (6.6)
18 (9.1)
17 (8.6)

6 (6.6)
7 (7.7)
6 (6.6)
5 (5.5)

6 (8.8)
6 (8.8)
10 (14.7)
10 (14.7)

3 (16.7)
0 (0.0)
1 (5.6)
0 (0.0)

1 (8.3)
0 (0.0)
1 (8.3)
1 (8.3)

1 (11.1)
0 (0.0)
0 (0.0)
1 (11.1)

* Frequencies may not add up to entire sample population (N=200) due to missing data based on race/ethnicity
Abbreviations: GED, general education diploma; OB/GYN, obstetrician/gynecologist
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Supplemental Table 2. Lipid screening characteristics among pregnant women from data
abstraction of electronic medical records stratified by non-Hispanic white and non-Hispanic
Black racial/ethnic subgroups
Overall
NH White
NH Black
P-Value†
(N=194)*
(N=35)
(N=12)
174.4 (28.5)
175.4 (26.4)
175.3 (34.5)
0.905
Total cholesterol, mg/dL‡
LDL-C, mg/dL
96.7 (25.8)
96.0 (20.7)
109.5 (33.2)
0.125
HDL-C, mg/dL
60.9 (13.4)
63.0 (13.7)
52.0 (9.7)
0.048
Triglycerides, mg/dL
84.2 (40.8)
82.5 (40.7)
67.7 (26.1)
0.124
* Six participants with absence of electronic medical records
† P-value represents statistical comparison between NH White and NH Black subgroups
‡ Cholesterol levels from outlier (n=1) with suspected untreated familial hypercholesterolemia excluded from
statistical analysis
Abbreviations: SD, standard deviation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol
Lipid Levels, mean (SD)†
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Supplemental Table 3. Demographic and clinical characteristics associated with a prior lipid
screening and an awareness of high cholesterol as a cardiovascular risk factor
Study Variables

Prior Lipid Screening
Yes
(N = 118)

No / Unsure
(N = 82)

P
Value
0.011

Awareness of High Cholesterol as
Risk Factor
Yes
No / Unsure
P
(N = 158)
(N = 42)
Value
0.041
100 (75.2)
33 (24.8)
57 (87.7)
8 (12.3)
0.702
13 (72.2)
5 (27.8)
62 (78.5)
17 (21.5)
80 (80.8)
19 (19.2)
<0.001
84 (92.3)
7 (7.7)
45 (66.2)
23 (33.8)
9 (75.0)
3 (25.0)
13 (72.2)
5 (27.8)
5 (55.6)
4 (44.4)
0.006
26 (65.0)
14 (35.0)
30 (71.4)
12 (28.6)
102 (86.4)
16 (13.6)
0.003
11 (57.9)
8 (42.1)
24 (75.0)
8 (25.0)
29 (80.6)
7 (19.4)
70 (92.1)
6 (7.9)
0.030
142 (81.6)
32 (18.4)
15 (62.5)
9 (37.5)
<0.001
128 (83.1)
26 (16.9)
8 (47.1)
9 (52.9)
0.006
57 (83.8)
11 (16.2)
81 (84.4)
15 (15.6)
19 (59.4)
13 (40.6)
0.300
24 (72.7)
9 (27.3)
134 (80.7)
32 (19.3)

Age, y
18 – 34
71 (53.4)
62 (46.6)
35+
47 (72.3)
18 (27.7)
Gestational age (weeks) at time of survey
0.341
1 – 13
9 (50.0)
9 (50.0)
14 – 27
43 (54.4)
36 (45.6)
28+
63 (63.6)
36 (36.4)
Race/Ethnicity
0.007
NH white
61 (67.0)
30 (33.0)
NH Black
29 (42.7)
39 (57.4)
Hispanic
10 (83.3)
2 (16.7)
Asian
12 (66.7)
6 (33.3)
Multiracial
4 (44.4)
5 (55.6)
Education
0.002
High school / GED or lower
14 (35.0)
26 (65.0)
Some college or higher
25 (59.5)
17 (40.5)
College graduate or above
79 (67.0)
39 (33.1)
Annual Household Income
0.066
Less than $20,000
9 (47.4)
10 (52.6)
$20,000 – $49,999
16 (50.0)
16 (50.0)
$50,000 – $99,999
22 (61.1)
14 (38.9)
More than $100,000
55 (72.4)
21 (27.6)
Usual Source of Care
0.307
Yes
106 (60.9)
68 (39.1)
No
12 (50.0)
12 (50.0)
Usual Care Provider Type
0.007
Primary care, family medicine
97 (63.0)
57 (37.0)
OB/GYN
5 (29.4)
12 (70.6)
Family History of High Cholesterol
0.239
Yes
45 (66.2)
23 (33.8)
No
52 (54.2)
44 (45.8)
Unsure
21 (65.6)
11 (34.4)
Family History of CVD
0.876
Yes
19 (57.6)
14 (42.4)
No
98 (59.0)
68 (41.0)
Past OB History
Gestational diabetes
12 (70.6)
5 (29.4)
0.310
13 (76.5)
4 (23.5)
Gestational hypertension
11 (84.6)
2 (15.4)
0.052
10 (76.9)
3 (23.1)
Preeclampsia
7 (38.9)
11 (61.1)
0.069
13 (72.2)
5 (27.8)
Premature birth (<37 weeks gestation)
5 (29.4)
12 (70.6)
0.010
10 (58.8)
7 (41.2)
Abbreviations: CVD, cardiovascular disease; GED, general education diploma; OB/GYN, obstetrician/gynecologist
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0.789
0.849
0.459
0.033

APPENDIX
Thank you for filling out this survey. Please answer all questions. When you are finished, please
return the survey to the research assistant.
First, we will ask you some questions about cholesterol testing and your use of health care service
before pregnancy.
1. What is your date of birth? _____ / ______ / ______ (MM / DD / YYYY)
2. Are you currently pregnant?
□ Yes
□ No
If you answered “Yes” to the above question, please answer the following:
3. How many weeks pregnant are you? ___________
4. Have you ever heard that high cholesterol is a risk factor for developing heart disease?
□ Yes
□ No
□ I don’t know
5. Have you ever been told that you have high cholesterol?
□ Yes
□ No
□ I don’t know
6. Have you ever had your cholesterol levels checked with a blood test?
□ Yes
□ No
□ I don’t know
If you answered “Yes” to the above question, please answer the following:
7. When did you last have them checked (approximately)?
□ Within past year
□ Within past 2 years
□ Within past 5 years
□ Within past 10 years
□ Longer than 10 years ago
8. Who ordered the test?
□ Primary care or family medicine provider
□ Cardiologist
□ Other, please describe: _____________________________

□ OBGYN
□ Pediatrician
□ I don’t know

9. What were you told about the results?
Cholesterol levels were:
□ normal
□ not normal
□ borderline
□ wasn’t told or I don’t remember
10. Does high cholesterol run in the family?
□ Yes
□ No
□ I don’t know
If you answered “Yes” to the above question, please answer the following:
11. Who in the family has high cholesterol?
□ Mother
□ Father
□ Brother
□ Sister
□ Grandparent
12. Have you ever been on cholesterol lowering medication?
□ Yes
□ No
□ I don’t know
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If you answered “Yes” to the above question, please answer the following:
13. Which cholesterol lowering medications have you taken?
□ Statins (Lipitor, Crestor)
□ Bile Acid Sequestrants (Colestid)
□ Niacin

□Ezetimibe (Zetia)
□ PSCK9 inhibitors (Repatha, Praluent)
□ Other, please describe: ________________________

Next, we will ask you some questions about your personal medical history and your family history.
14. Is there a doctor or other health care provider that you see regularly for check-ups or health
maintenance when you are not pregnant?
□ Yes
□ No
If you answered “Yes” to the above question, please answer the following:
15. What kind of health care provider do you see?
□ Primary care, internal medicine, or family medicine provider □ OBGYN
□ Cardiologist
□ Pediatrician
□ Other, please describe: ___________________________
□ I don’t know
16. Is this health care provider in the PENN system?
□ Yes
□ No
□ I don’t know
If you answered “No” to the above question, please answer the following:
17. When is the last time you saw a health care provider for a routine check-up or health
maintenance visit?
□ More than 1 year ago
□ More than 3 years ago
□ More than 5 years ago
□ I don’t remember
18. Do you have any male first degree relatives (father, brother or son) who had a heart attack, stroke, or
coronary artery disease that occurred before the age of 50 years?
□ Yes
□ No
□ I don’t know
19. Do you have any female first degree relatives (mother, sister, daughter) who had a heart attack,
stroke, or coronary artery disease that occurred before the age of 60 years?
□ Yes
□ No
□ I don’t know
20. Have you ever had any of the following conditions during this pregnancy or a prior pregnancy?
□ Gestational diabetes
□ Gestational hypertension
□ Preeclampsia
21. Have you ever delivered a baby prematurely (before 37 weeks gestation)?
□ Yes
□ No
If yes to above question:
How many weeks pregnant were you when you delivered? __________
22. Do you currently smoke cigarettes or use tobacco most days of the week?
□ Yes
□ No
If you answered “No” to the above question, please answer the following:
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Did you smoke or use tobacco most days of the week before pregnancy?
□ Yes
□ No
23. What was your weight prior to pregnancy? ________ (in pounds)
Next, we want to know your opinion about cholesterol screening in pregnancy.
Cholesterol levels are measured with a blood test. High cholesterol is a risk factor for developing heart
disease. Unfortunately, many women do not receive the recommended screening for cholesterol during
their reproductive years. We would like to know how you would feel about your OBGYN checking your
cholesterol levels during early pregnancy to see if you are at risk. These results would not impact your
pregnancy but might change your care after you deliver. For example, if you had high cholesterol, your
OBGYN might be more likely to refer you to a primary care doctor to learn about ways to lower your
cholesterol through healthy diet and exercise. In rare cases, the cholesterol level might be high enough for
a referral to see a doctor specializing in cholesterol disorders.
Given this information, please respond to the following statement. Your answer is confidential and will
not impact the care you receive from your doctors.
24. I would like my OBGYN to check my cholesterol levels during early pregnancy, at the same time that
I am getting my blood drawn for other necessary tests.
□ Strongly agree □ Agree
□ Neutral
□ Disagree
□ Strongly disagree
Finally, we want to ask you a few questions about your background.
25. What is your race?
□ White □ Black □ Asian
26. What is your ethnicity?
□ Hispanic
□ Non-Hispanic

□ Native American

□ Multiracial

□ Prefer not to answer

□ Prefer not to answer

27. What is your highest level of education completed?
□ Less than 12th grade □ High school or GED □ Some college or associate degree
□ College graduate or above
□ Prefer not to answer
28. What is your annual household income?
□ Less than $20,000
□ $20,000 - $49,999
□ Prefer not to answer

□ $50,000 - $99,999

□ More than $100,000

Thank you for completing the survey.
If you have any feedback for us, please provide write your comments below.
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